- Metelimumab
-
Metelimumab ? Monoclonal antibody Type Whole antibody Source Human Target TGF beta 1 Clinical data Pregnancy cat. ? Legal status ? Identifiers CAS number 272780-74-2 
ATC code None Chemical data Formula ? 
(what is this?) (verify)Metelimumab (CAT-192) is a human IgG4 monoclonal antibody that neutralizes TGF beta 1 which had been chosen for further development for the treatment of diffuse cutaneous systemic sclerosis, also known as scleroderma. Touted as a drug of the future,[1] Metelimumab was dropped from further development in favour of GC-1008,[2] which is currently being developed by Genzyme.[3]
History
CAT-192 was isolated by Cambridge Antibody Technology using its phage display technology. In 2000, Cambridge Antibody Technology signed a collaborative deal with Genzyme to further develop TGF beta antibodies.[4][5]
In 2004, Cambridge Antibody Technology and Genzyme revealed that Phase I/II trials of CAT-192 for scleroderma showed the human anti-TGF-Beta1 monoclonal antibody to be safe and well tolerated across all dose levels, although no conclusions regarding efficacy of the compound could be made.[6]
Initial trials targeted the skin condition scleroderma[7] but, after some unsuccessful clinical trial results, the product was dropped in favour of GC-1008,[2] which is currently being developed by Genzyme.[3]
References
- ^ http://journals.prous.com/journals/servlet/xmlxsl/pk_journals.xml_summary_pr?p_JournalId=2&p_RefId=860002&p_IsPs=N
- ^ a b http://www.independent.co.uk/news/business/news/cat-may-abandon-skin-drug-after-trial-results-disappoint-569445.html
- ^ a b http://www.genzymeoncology.com/onc/research/onc_p_research.asp
- ^ http://prnwire.com/cgi-bin/stories.pl?ACCT=104&STORY=/www/story/09-28-2000/0001324438&EDATE=
- ^ http://www.drugdiscoveryonline.com/article.mvc/Cambridge-Antibody-Genzyme-to-collaborate-on-0001?VNETCOOKIE=NO
- ^ http://goliath.ecnext.com/coms2/gi_0199-693661/CAT-192-is-safe-but.html
- ^ http://www.genzymeoncology.com/onc/clinical/trialdetailresults.asp?nct=NCT00043706
Monoclonal antibodies for the immune system Immune system ("-l(i[m])-") Human ("-limu-")immunosuppression: Adalimumab • Atorolimumab • Brodalumab • Carlumab • Fresolimumab • Golimumab • Lerdelimumab • Mavrilimumab • Metelimumab • Morolimumab • Namilumab • Oxelumab • Sarilumab • Sifalimumab • Tabalumab • Urelumab
immune activation: Ipilimumab • Tremelimumab
other: Bertilimumab • ZanolimumabMouse ("-limo-")Chimeric ("-lixi-")Basiliximab • Clenoliximab • Galiximab • Gomiliximab • Infliximab • Keliximab • Lumiliximab • Priliximab • Teneliximab • VapaliximabHumanized ("-lizu-")immunosuppressive: Aselizumab • Apolizumab • Benralizumab† • Cedelizumab • Certolizumab pegol • Daclizumab • Eculizumab • Efalizumab • Epratuzumab • Erlizumab • Etrolizumab • Fontolizumab • Itolizumab • Mepolizumab • Mogamulizumab • Natalizumab • Ocrelizumab • Omalizumab • Ozoralizumab • Pascolizumab • Pateclizumab • Pexelizumab • PRO 140† • Reslizumab • Rontalizumab • Rovelizumab • Ruplizumab • Samalizumab • Siplizumab • Talizumab • Teplizumab • Tocilizumab • Toralizumab • Tregalizumab • Vatelizumab • Vedolizumab • Visilizumab • TGN1412§
non-immunosuppressive: Ibalizumab†Chimeric + humanized
("-lixizu-")Interleukin ("-k(i[n])-") Human ("-kinu-")Briakinumab • Canakinumab • Fezakinumab • Secukinumab • Sirukumab • Tralokinumab • UstekinumabHumanized ("-kizu-", "-kinzu-")Anrukinzumab • Enokizumab • Gevokizumab • Ixekizumab • Lebrikizumab • OlokizumabInflammatory lesions ("-les-") Mouse ("-leso-")
This monoclonal antibody-related article is a stub. You can help Wikipedia by expanding it. This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.
